Scalper1 News
The FDA approved Gilead Sciences’ (GILD) hepatitis C combo pill Harvoni Friday afternoon, in a widely expected but still crucial step for a drug expected to be a megablockbuster. Gilead also disclosed the drug’s price for the first time, at $94,500 for a 12-week course. Harvoni is a combination of ledipasvir and sofosbuvir, the latter already being sold solo under the brand name Sovaldi. Sovaldi, launched in December, has already raked in a Scalper1 News
Scalper1 News